UK & World

The Moderna vaccine is 90% effective in preventing infection 6 months after the last dose.

Moderna’s COVID-19 vaccine is 90% effective in preventing infection 6 months after the last dose.

  • Updated data from Moderna’s Phase III clinical trials show that the vaccine is 90% effective in preventing COVID-19 infection 6 months after the second dose.
  • Shot was also more than 95% to prevent severe illness after 6 months
  • The level of effectiveness is slightly lower than the 94.5% reported last year, but it still shows that Moderna provides long-term protection.
  • This brings Moderna one step closer to applying for full approval to the FDA after it was approved for emergency use in 2020.
  • Moderna is still waiting for data on how well vaccine boosters work and how effective vaccines are among children aged 6 months to 17 years.

Modana According to Inc, the vaccine is more than 90% protective. COVID-19 (New Coronavirus Infection) 6 months after the second dose.

In the latest data from a phase III clinical trial released Tuesday, the company also said that jabs were more than 95% effective against serious illness 24 weeks after receiving the final dose.

With the new data, Moderna is approaching a full approval application with the US Food and Drug Administration (FDA).

The vaccine was approved for emergency use by people over the age of 18 in December 2020, but safety data were only two months.

Although the level of efficacy is slightly lower than the 94.5 percent reported last year, the data show that the vaccine provides long-term protection.

New data from Moderna’s Phase III clinical trials show that the vaccine is 90% effective in preventing COVID-19 infection 6 months after the second dose.Photo: Healthcare worker holding a Vial of Moderna COVID-19 vaccine in New York City, January 2021

As US vaccination campaigns continue to grow, they have been more than 95% effective in preventing serious illnesses six months later.

As US vaccination campaigns continue to grow, they have been more than 95% effective in preventing serious illnesses six months later.

The updated data comes after a study published by a team at Duke University in the New England Journal of Medicine showed that antibodies produced by the Modana vaccine were present for as long as 6 months after the last dose. is.

These are very similar to the findings reported by Pfizer-BioNTech, which uses a technology similar to vaccines.

The new data examined 900 cases of COVID-19 reported among participants in Moderna’s late clinical trials.

However, a company based in Cambridge, Massachusetts did not identify how many of these cases were in the vaccine recipient and how many were in the placebo group.

Moderna is still conducting several vaccine trials, including vaccine trials for children under the age of 17 and vaccine booster tests.

Currently, the exam for children aged 12 to 17 is fully enrolled in the United States with approximately 3,000 participants.

Meanwhile, exams between the ages of 6 months and 11 are currently enrolled and will be capped at 6,750 participants in the United States and Canada.

In addition, earlier this month, the National Institutes of Health (NIH) will test booster shots of Moderna Inc’s coronavirus vaccine early to see if it provides better protection against highly contagious mutants from South Africa. Staged clinical trials have begun.

Approximately 210 healthy adult volunteers will be enrolled in four clinical research sites: Atlanta, Cincinnati, Nashville, and Seattle.

In the new study, volunteers will receive three booster shots, a modified version of Moderna’s original vaccine.

One-third of the participants will receive a 50 microgram (µg) booster candidate called mRNA-1273.351.

An additional third will receive a higher dose of the candidate, 100 µg.

The last group is given a shot called mRNA-1273.211. This is a combination of Moderna’s original vaccine and booster shots in a single dose.

The updated data are after studies have shown that the antibodies produced by the Moderna vaccine are still present 6 months after the last dose (above).

The updated data are after studies have shown that the antibodies produced by the Moderna vaccine are still present 6 months after the last dose (above).

Researchers evaluate the safety of boosters and whether they can elicit an immune response.

It also looks for potential side effects such as redness and pain at the injection site, fever, headache, malaise, and muscle aches.

“The Moderna team continues to make significant progress with the COVID-19 vaccine,” CEO Stéphane Bancel said in a statement.

“We look forward to obtaining clinical data from variant-specific booster candidates and from Phase 2/3 trials of the COVID-19 vaccine in adolescence.

“New preclinical data on variant-specific vaccine candidates gives us confidence that we can actively work on new variants. Moderna is only needed for the COVID-19 vaccine until the pandemic is controlled. I will update it.

Advertising

The Moderna vaccine is 90% effective in preventing infection 6 months after the last dose.

Source link The Moderna vaccine is 90% effective in preventing infection 6 months after the last dose.

Related Articles

Back to top button